SAN DIEGO, Feb. 11, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, will host an investor ...
One stock that might be an intriguing choice for investors right now is AnaptysBio, Inc. ANAB. This is because this security in the Medical - Biomedical and Genetics space is seeing solid earnings ...
The firm increased its portfolio allocation in ANAB by 55.02% over the last quarter. Frazier Life Sciences Management holds 2,209K shares representing 7.26% ownership of the company. In its prior ...
Wedbush analyst David Nierengarten maintained a Buy rating on AnaptysBio (ANAB – Research Report) today and set a price target of $40.00. The company’s shares closed yesterday at $16.08.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback